Literature DB >> 35579711

Performance of adding hepatobiliary phase image in magnetic resonance imaging for detection of hepatocellular carcinoma: a meta-analysis.

Jielin Pan1,2, Wenjuan Li2, Lingjing Gu1, Chaoran Liu2, Ke Zhang2, Guobin Hong3.   

Abstract

OBJECTIVES: To determine the performance of diagnostic algorithm of adding hepatobiliary phase (HBP) images in Gd-EOB-DTPA-enhanced MRI for the detection of hepatocellular carcinoma (HCC) measuring up to 3 cm in patients with chronic liver disease.
METHODS: We searched multiple databases from inception to April 10, 2020, to identify studies on using Gd-EOB-DTPA-enhanced MRI for the diagnostic accuracy of HCC (≤ 3 cm) in patients with chronic liver disease. The diagnostic algorithm of Gd-EOB-DTPA-enhanced MRI with HBP for HCC was defined as a nodule showing hyperintensity during arterial phase and hypointensity during the portal venous, delayed, or hepatobiliary phases. For gadoxetic acid-enhanced MRI without HBP, the diagnostic criteria were a nodule showing arterial enhancement and hypointensity on the portal venous or delayed phases. The data were extracted to calculate summary estimates of sensitivity, specificity, diagnostic odds ratio, likelihood ratio, and summary receiver operating characteristic (sROC) by using a bivariate random-effects model.
RESULTS: Twenty-nine studies with 2696 HCC lesions were included. Overall Gd-EOB-DTPA-enhanced MRI with HBP had a sensitivity of 87%, specificity of 92%, and the area under the sROC curve of 95%. The summary sensitivity of Gd-EOB-DTPA-enhanced MRI with HBP was significantly higher than that without HBP (84% vs 68%, p = 0.01).
CONCLUSION: Gd-EOB-DTPA-enhanced MRI with HBP showed higher sensitivity than that without HBP and had comparable specificity for diagnosis of HCC in patients with chronic liver disease. KEY POINTS: • Hypointensity on HBP is a major feature for diagnosis of HCC. • Extending washout appearance to the transitional or hepatobiliary phase on Gd-EOB-DTPA provides favorable sensitivity and comparable specificity for diagnosis HCC. • The summary sensitivity of gadoxetic acid-enhanced MRI with HBP was significantly higher than that without HBP (84% vs 68%, p = 0.01) for diagnosis of HCC in patients with chronic liver disease.
© 2022. The Author(s), under exclusive licence to European Society of Radiology.

Entities:  

Keywords:  Diagnostic performance; Gadoxetic acid; Hepatocellular carcinoma; Magnetic resonance imaging; Meta-analysis

Year:  2022        PMID: 35579711     DOI: 10.1007/s00330-022-08826-z

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  47 in total

1.  Consensus report of the Fifth International Forum for Liver MRI.

Authors:  Christoph J Zech; Carlo Bartolozzi; Paulette Bioulac-Sage; Pierce K Chow; Alejandro Forner; Luigi Grazioli; Alexander Huppertz; Herve Laumonier; Jeong Min Lee; Takamichi Murakami; Jens Ricke; Claude B Sirlin
Journal:  AJR Am J Roentgenol       Date:  2013-07       Impact factor: 3.959

2.  Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.

Authors:  Jorge A Marrero; Laura M Kulik; Claude B Sirlin; Andrew X Zhu; Richard S Finn; Michael M Abecassis; Lewis R Roberts; Julie K Heimbach
Journal:  Hepatology       Date:  2018-08       Impact factor: 17.425

3.  Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma.

Authors:  Luigi Bolondi; Stefano Gaiani; Natascia Celli; Rita Golfieri; Walter Francesco Grigioni; Simona Leoni; Anna Maria Venturi; Fabio Piscaglia
Journal:  Hepatology       Date:  2005-07       Impact factor: 17.425

4.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.

Authors:  Jacques Ferlay; Hai-Rim Shin; Freddie Bray; David Forman; Colin Mathers; Donald Maxwell Parkin
Journal:  Int J Cancer       Date:  2010-12-15       Impact factor: 7.396

Review 5.  Primovist, Eovist: what to expect?

Authors:  Bernard E Van Beers; Catherine M Pastor; Hero K Hussain
Journal:  J Hepatol       Date:  2012-04-12       Impact factor: 25.083

6.  Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma.

Authors:  Alejandro Forner; Ramón Vilana; Carmen Ayuso; Lluís Bianchi; Manel Solé; Juan Ramón Ayuso; Loreto Boix; Margarita Sala; María Varela; Josep M Llovet; Concepció Brú; Jordi Bruix
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

7.  Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy.

Authors:  Hiroshi Imamura; Yutaka Matsuyama; Eiji Tanaka; Takao Ohkubo; Kiyoshi Hasegawa; Shinichi Miyagawa; Yasuhiko Sugawara; Masami Minagawa; Tadatoshi Takayama; Seiji Kawasaki; Masatoshi Makuuchi
Journal:  J Hepatol       Date:  2003-02       Impact factor: 25.083

Review 8.  CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features.

Authors:  Jin-Young Choi; Jeong-Min Lee; Claude B Sirlin
Journal:  Radiology       Date:  2014-10       Impact factor: 11.105

9.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

10.  Analysis of the recurrence risk factors for the patients with hepatocellular carcinoma meeting University of California San Francisco criteria after curative hepatectomy.

Authors:  Ruey-Shyang Soong; Ming-Chin Yu; Kun-Ming Chan; Hong-Shiue Chou; Ting-Jung Wu; Chen-Fang Lee; Tsung-Han Wu; Wei-Chen Lee
Journal:  World J Surg Oncol       Date:  2011-01-27       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.